Press releases
-
07/30/2026, Sophia Antipolis, France Median Technologies and Olea Medical, a Canon Medical Systems Company, Partner to Advance Commercial Deployment of AI-Powered eyonis® LCS for Lung Cancer Screening
Following FDA 510(k) clearance and CE marking for eyonis® LCS, Median is now focused on accelerating the product’s commercial adoption in the United States and Europe.Read more Download 20260730_PR_CanonOlea_Median_EN_final-1.pdf -
07/22/2026, Sophia Antipolis, France Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications across the eyonis® Portfolio
Median Technologies today announced its key financial performance for the first half of 2026 and highlighted major regulatory and commercial achievements for eyonis® LCS.Read more Download 20260722_PR_H12026keyfigures_EN.pdf -
07/15/2026, Sophia Antipolis, France Half Year Median Technologies liquidity contract statement – First half of 2026
Median Technologies provides the half year liquidity contract statement for the first half of 2026Read more Download 20260715_PR_LiquiditycontractH12026_EN.pdf -
07/06/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of June 30, 2026
Disclosure of total number of voting rights and number of shares in the capital as of June 30, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20260706_PR_shares_votingrights_June2026-1.pdf -
07/03/2026, Sophia Antipolis, France Median Technologies’ eyonis® LCS Obtains CE Marking
eyonis® LCS has obtained CE marking as a Class IIb medical device, under the new European Medical Device Regulation (MDR 2017/745), enabling commercialization across the European Economic Area.Read more Download 20260703_PR_eyonis_CEMark_EN_final.pdf -
06/08/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of May 31, 2026
Disclosure of total number of voting rights and number of shares in the capital as of May 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20260608_PR_shares_votingrights_May2026.pdf -
06/03/2026, Sophia Antipolis, France Success of Median’s Capital Increase
Median Technologies Announces Successful Upsized Capital Increase of € 50 Million. This communication and the information and documents relating to it may not be distributed, directly or indirectly, in the United States or in any other jurisdiction where such distribution is not permitted.Read more -
06/01/2026, Sophia Antipolis, France Median Technologies Brings Forward Subscription Period of its €50 Million Capital Increase on the Back of Strong Demand from Institutional Investors
Median Technologies Brings Forward Subscription Period of its €50 Million Capital Increase on the Back of Strong Demand from Institutional Investors. This communication and the information and documents relating to it may not be distributed, directly or indirectly, in the United States or in any other jurisdiction where such distribution is not permitted.Read more -
05/27/2026, Sophia Antipolis, France Launch of a capital increase
Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis® Pan-Cancer Early Diagnostics Suite. This communication and the information and documents relating to it may not be distributed, directly or indirectly, in the United States or in any other jurisdiction where such distribution is not permitted.Read more -
05/26/2026, Sophia Antipolis, France Median Technologies to showcase iCRO’s central and AI-powered imaging services for oncology clinical trials at ASCO 2026
The Company will be participating in the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, McCormick Place, Chicago, IL, USA.Read more Download 20260526_PR_ASCO2026_EN.pdf